Dark

Check out our Dark Pool Levels

CHMA
Chiasma, Inc. Common Stock
stock NASDAQ

Inactive

Aug 5, 2021

3.76USD-6.000%(-0.24)8,196,718

Pre-market

0.00USD-100.000%(-4.00)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jun 29, 2021

07:03AM EDT Chiasma Files Mycapssa European Application For Acromegaly Benzinga

Jun 28, 2021

04:13PM EDT Chiasma Reports Submission Of Marketing Authorization Application For MYCAPSSA To European Medicines Agency Benzinga

04:12PM EDT Chiasma Announces Submission of Marketing Authorization GlobeNewswire Inc

Jun 24, 2021

12:26PM EDT SHAREHOLDER ALERT: WeissLaw LLP Reminds ARPO, ONDS, CHMA, and PFOH GlobeNewswire Inc

Jun 17, 2021

10:57AM EDT SHAREHOLDER ALERT: WeissLaw LLP Reminds ONDS, CHMA, PFOH, and HGV GlobeNewswire Inc

Jun 10, 2021

12:12PM EDT SHAREHOLDER ALERT: WeissLaw LLP Reminds CHMA, PFOH, PTON, and HGV GlobeNewswire Inc

May 28, 2021

08:02AM EDT Chiasma's Mycapssa Associated With Positive Patient-Reported Outcomes In Acromegaly Patients Benzinga

May 27, 2021

04:12PM EDT Chiasma Highlights Presentation Of Patient-Reported Outcomes Data From MPOWERED Phase 3 Trial At Annual American Association Of Clinical Endocrinology Meeting Benzinga

04:05PM EDT Chiasma Presents Positive Patient-Reported Outcomes Data from its GlobeNewswire Inc

May 26, 2021

03:40PM EDT SHAREHOLDER ALERT: WeissLaw LLP Reminds CHMA, PFOH, PTON, and HGV GlobeNewswire Inc

07:33AM EDT The Daily Biotech Pulse: Nabriva Jumps On Data, Larimar Wilts After Study Put On Hold, Travere To Delay Regulatory Filing Benzinga

May 23, 2021

10:06AM EDT The Week Ahead In Biotech (May 23-29): Eton, Lantheus FDA Decisions, Adcom Test For Provention, Chiasma Data Presentation Benzinga

May 20, 2021

08:04AM EDT Chiasma Highlights Presentation Of New Data From MPOWERED Phase 3 Trial At Upcoming European Congress of Endocrinology, Annual American Association of Clinical Endocrinology Meetings May 24-27 Benzinga

08:00AM EDT -- New clinical data accepted for oral and e-Poster presentation atAACE -- GlobeNewswire Inc

May 13, 2021

04:04PM EDT Acentrus Specialty Contracts With Chiasma to Bring MYCAPSSA to Health Systems and Hospitals in the Acentrus Network Benzinga

May 7, 2021

06:30PM EDT CHIASMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chiasma, Inc. - CHMA Business Wire

May 6, 2021

07:49AM EDT The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom Benzinga

May 5, 2021

02:52PM EDT Mid-Afternoon Market Update: Dow Surges 180 Points; Big 5 Sporting Goods Shares Spike Higher Benzinga

12:17PM EDT Mid-Day Market Update: Crude Oil Rises 1%; Esperion Therapeutics Shares Drop Following Q1 Results Benzinga

10:26AM EDT Mid-Morning Market Update: Markets Mostly Lower; General Motors Profit Beats Estimates Benzinga

08:00AM EDT Chiasma Stock Shoots Up On Being Acquired By Amryt Pharma In All Stock Deal Benzinga

07:52AM EDT Chiasma Stock Shoots Up On Amryt's All Stock Acquisition To Strengthen Position In Rare & Orphan Diseases Benzinga

07:43AM EDT The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues Benzinga

07:37AM EDT Chiasma Q1 EPS $(0.49) Misses $(0.31) Estimate Benzinga

07:23AM EDT UPDATE: Amryt To Exchange 0.396 Amryt ADS Per 1 Chiasma Common Stock Benzinga

07:23AM EDT Amryt Reports Will Purchase Chiasma In Stock Deal Benzinga

07:09AM EDT Amryt Signs Definitive Agreement To Acquire Chiasma In An All-stock Combination RTTNews

07:05AM EDT Chiasma Reports First Quarter Financial Results and Announced GlobeNewswire Inc

07:04AM EDT UPDATE: Amryt To Exchange 0.396 Amryt ADS Per 1 Chiasma Common Stock Benzinga

07:03AM EDT Amryt Reports Will Purchase Chiasma In Stock Deal Benzinga

07:00AM EDT - Combined business will have three approved commercial products, lomitapide (Lojuxta/Juxtapid), metreleptin (Myalept/ Myalepta), octreotide (MYCAPSSA) and a robust clinical pipeline GlobeNewswire Inc

Apr 29, 2021

08:00AM EDT Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast onThursday, May 6, 2021at5:00 pm Eastern Timeto discuss financial results for the quarter ended March 31, 2021and to provide a business update. GlobeNewswire Inc

Mar 30, 2021

08:06AM EDT The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings Benzinga

Mar 23, 2021

11:26AM EDT Chiasma shares were trading higher after the company presented long-term safety and efficacy data from the first 48 weeks of the open-label extension of the Phase 3 CHIASMA OPTIMAL trial of MYCAPSSA at ENDO 2021. Benzinga

08:18AM EDT The Daily Biotech Pulse: FDA Approvals For Merck, Pacira And Zealand, Roche-Regeneron Ace Late-Stage COVID-19 Study, AlloVir Appoints Gilead Virology Chief As CEO Benzinga

Mar 22, 2021

04:02PM EDT Chiasma Offers Long-Term Safety, Efficacy Data From Open-Label Extension Study Of Its Phase 3 Trial Of MYCAPSSA Candidate: '93% of all patients who enrolled as a responder to MYCAPSSA maintained their biochemical response' Benzinga

04:01PM EDT --93% of all patients who enrolled as a responder to MYCAPSSA maintained their biochemical response at the end of the 48-week open-label extension (OLE) period-- GlobeNewswire Inc

08:42AM EDT Chiasma's Mycapssa Improves Acromegaly Related Symptoms After Switching From iSRLs Benzinga

Mar 20, 2021

11:41AM EDT Chiasma Presents Positive Data For MYCAPSSA From Phase 3 Trial MPOWERED For Maintenance Treatment Of Acromegaly At ENDO RTTNews

11:00AM EDT --Data supports MYCAPSSA as non-inferior to long-actinginjectable somatostatin receptor ligands (iSRLs)-- GlobeNewswire Inc

Mar 10, 2021

08:00AM EST Chiasma to Present New Data from Two Phase 3 Trials, CHIASMA GlobeNewswire Inc

Mar 4, 2021

04:02PM EST Chiasma Q4 EPS $(0.32) Beats $(0.35) Estimate, Sales $964.00K Miss $1.00M Estimate Benzinga

04:01PM EST Phased launch of MYCAPSSA progressing with 2020 net product revenue of $1.1 million GlobeNewswire Inc

08:12AM EST The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company Benzinga

04:07AM EST Earnings Scheduled For March 4, 2021 Benzinga

Mar 2, 2021

08:00AM EST Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company, today announced that management will present a company overview at the H.C. Wainwright Global Life Sciences Conference, which is being held Tuesday, March 9th - Wednesday, March 10th, 2021. GlobeNewswire Inc

Feb 27, 2021

09:04PM EST The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings Benzinga

Feb 25, 2021

08:00AM EST Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company, today announced that it will host a conference call and live audio webcast on Thursday, March 4, 2021 at 5:00 pm Eastern Time to discuss financial results for the quarter and year ended December 31, 2020 and to provide a business update. GlobeNewswire Inc

Jan 19, 2021

07:03AM EST Chiasma Announces Hiring of John Doyle as Chief Financial Officer Benzinga

Jan 6, 2021

04:02PM EST Chiasma Sees FY20 Sales $900K-$1.1M vs $1.09M Estimate Benzinga

04:02PM EST Chiasma Offers Expected 2021 Milestones Benzinga

04:01PM EST MYCAPSSA launch in US continuing to gain traction with physicians, patients, and payers GlobeNewswire Inc

Nov 23, 2020

08:00AM EST Chiasma to Participate in Two Investor Conferences in December GlobeNewswire Inc

Nov 20, 2020

08:00AM EST Chiasma to Host an Expert Panel on Acromegaly and the GlobeNewswire Inc

Nov 18, 2020

10:14AM EST Shares of Chiasma, Inc. (CHMA) gained over 8% on Wednesday morning after reporting positive results from a late-stage trial of treatment for Acromegaly. RTTNews

07:30AM EST The Daily Biotech Pulse: Kazia Jumps On Data Readout, Clinical Hold On Cellectis' Blood Cancer Study Lifted Benzinga

07:12AM EST Chiasma Announces MPOWERED Phase 3 Clinical Trial Met Its Primary Non-Inferiority Endpoint; Says '91% of patients on MYCAPSSA maintained IGF-1 response in the 9-month randomized, controlled phase of the non-inferiority trial' Benzinga

07:00AM EST 91% of patients on MYCAPSSA maintained IGF-1 response in the 9-month randomized, controlledphaseof the non-inferiority trial GlobeNewswire Inc

Nov 16, 2020

08:00AM EST Chiasma to Participate in the Jefferies Virtual London Healthcare GlobeNewswire Inc

Nov 5, 2020

04:53PM EST Chiasma Q3 EPS $(0.30) Beats $(0.39) Estimate Benzinga

03:57PM EST Notable Earnings Watchlist For Thursday, Nov. 5, 2020 After Market Close: NLOK, TTWO, Z, SYNA, GPRO, DBX, NWS, PTON, MCHP, MNST, UBER, YELP, WLL, WYNN, SQ, ROKU, BKNG, BMRN, CHMA, CHUY, AIG, GRPN, FLS, FLT, IAC, EA, ENDP Benzinga

07:54AM EST The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping Benzinga

04:34AM EST Earnings Scheduled For November 5, 2020 Benzinga

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 30, 2020

08:00AM EDT Chiasma, Inc. (NASDAQ: CHMA) today recognizes Acromegaly Awareness Day, which is observed every year on November 1, and reiterates its commitment to people with acromegaly and the patient advocacy groups in their ongoing efforts to increase awareness of acromegaly and support the unique needs of people living with acromegaly. GlobeNewswire Inc

Oct 29, 2020

08:00AM EDT Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company, today announced that it will host a conference call and live audio webcast on Thursday, November 5, 2020 at 5:00 pm Eastern Time to discuss financial results for the quarter ended September 30, 2020 and to provide a business update. GlobeNewswire Inc

Oct 1, 2020

07:07AM EDT Chiasma Announces Planned Transition Of Former CEO Benzinga

Sep 8, 2020

08:00AM EDT Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop oral therapies to reduce the burden of chronic injections for people with rare diseases, today announced that management will be participating in two investor conferences in September. GlobeNewswire Inc

Aug 31, 2020

08:06AM EDT Chiasma Reports U.S. Commercial Launch And Availability Of MYCAPSSA RTTNews

08:03AM EDT Chiasma Announces US Commercial Launch And Availability Of MYCAPSSA Oral Somatostatin Analog For Patients With Acromegaly Benzinga

08:00AM EDT Chiasma Announces U.S. Commercial Launch and Availability of GlobeNewswire Inc

Aug 17, 2020

08:16AM EDT Chiasma Reports Publication Of Pivotal Data From Phase 3 CHIASMA OPTIMAL Clinical Trial RTTNews

08:06AM EDT Chiasma Announces Publication of Pivotal Data from the Phase 3 CHIASMA OPTIMAL Clinical Trial in the Journal of Clinical Endocrinology & Metabolism Benzinga

08:00AM EDT Chiasma Announces Publication of Pivotal Data from the Phase 3 GlobeNewswire Inc

Aug 13, 2020

09:33AM EDT Benzinga's Top Upgrades, Downgrades For August 13, 2020 Benzinga

06:12AM EDT Jefferies Initiates Coverage On Chiasma with Buy Rating, Announces Price Target of $8 Benzinga

Aug 12, 2020

06:45AM EDT HC Wainwright & Co. Maintains Buy on Chiasma, Lowers Price Target to $10 Benzinga

Aug 10, 2020

04:42PM EDT Chiasma Q2 EPS $(0.50) Misses $(0.38) Estimate Benzinga

04:06PM EDT Chiasma Reports Second Quarter 2020 Results and Significant GlobeNewswire Inc

04:10AM EDT Earnings Scheduled For August 10, 2020 Benzinga

Aug 3, 2020

04:01PM EDT Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company, today announced that it will host a conference call and live audio webcast on Monday, August 10, 2020 at 5:00 p.m. Eastern Time to discuss financial results for the quarter ended June 30, 2020 and to provide a business update. GlobeNewswire Inc

Jul 27, 2020

04:05PM EDT UPDATE: Chiasma Says Mean Of IGF-1 Levels For Population Of All MYCAPSSA-Treated Patients That Completed 36-Week Core CHIASMA OPTIMAL Trial And Continued Into OLE 'was maintained within normal limits at the end of the 48-week OLE period' Benzinga

04:03PM EDT UPDATE: Chiasma Says 'All MYCAPSSA responders (IGF-1 within normal limits) who enrolled into the OLE completed the 48-week period; 93% maintained their response at the end of this period; Benzinga

04:03PM EDT Chiasma Announces 48-Week Safety And Efficacy Data From Open-Label Extension Study Of CHIASMA OPTIMAL Phase 3 Trial Evaluating MYCAPSSA Benzinga

04:01PM EDT -- The mean of the IGF-1 levels for the population of all MYCAPSSA treated patients that completed the 36-week core CHIASMA OPTIMAL trial and continued into the open-label extension (OLE) (n=19) was maintained within normal limits at the end of the 48-week OLE period -- GlobeNewswire Inc

Jul 17, 2020

05:08AM EDT 64 Biggest Movers From Yesterday Benzinga

Share